Tenderwize
Retour à la recherche

Open House Originale Rabattverträge 2025-02- Elvitegravir/Cobicistat/Emtricitabin/Tenofoviralafenamidfumarat (Genvoya(R))

Techniker Krankenkasse·Hamburg, Germany·Deadline Feb 27, 2027 · 185 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-02- Elvitegravir/Cobicistat/Emtricitabin/Tenofoviralafenamidfumarat (Genvoya(R))

15/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

15 / 100

Complexité

20 / 100

Facteurs de risque

No estimated value, framework maximum, or lot values provided. Cannot estimate potential revenue.

Contract automatically ends upon patent expiry/loss of market exclusivity of Genvoya®. At that point, generic competiti...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Feb 2027
  • Supply of the pharmaceutical product Genvoya® (Elvitegravir/Cobicistat/Emtricitabin/Tenofoviralafenamidfumarat) under discount agreements
  • Participation open to any pharmaceutical company that markets or intends to market Genvoya® in Germany
Afficher le résumé complet

Open House procedure by Techniker Krankenkasse (TK) and other German health insurers to conclude discount agreements under §130c SGB V for the active ingredient combination Elvitegravir/Cobicistat/Emtricitabin/Tenofoviralafenamidfumarat (Genvoya®). The procedure allows any eligible pharmaceutical company to join at any time during the 24-month contract period (01.03.2025 – 28.02.2027). No negotiation on terms; standard conditions apply. No exclusivity. The notice indicates this is not a public procurement subject to EU directives but published voluntarily. Value not disclosed.

Risques

No estimated value, framework maximum, or lot values provided. Cannot estimate potential revenue.

Contract automatically ends upon patent expiry/loss of market exclusivity of Genvoya®. At that point, generic competiti...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Participant must be a pharmaceutical entrepreneur as defined in §4(18) AMG with respect to the offered drug
  • Must have a valid marketing authorization for Genvoya® or be otherwise entitled to place it on the market in Germany
  • Seat must be in Germany, EU/EEA

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria – all eligible participants are accepted.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open House Originale Rabattverträge 2025-02- Elvitegravir/Cobicistat/Emtricitabin/Tenofoviralafenamidfumarat (Genvoya(R))

Single lot covering discount agreements for the fixed-dose combination Genvoya®. Contract duration max 24 months starting 01.03.2025, ends automatically at patent expiry or earlier.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Feb 2025 - Feb 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria – all eligible participants are accepted.

Date limite

Deadline Feb 27, 2027

Détails de la procédure

Date de publication
20 Jan 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
41398-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3